<DOC>
	<DOCNO>NCT01478048</DOCNO>
	<brief_summary>The purpose study determine whether addition Elotuzumab Bortezomib/ Dexamethasone prolong time myeloma worsens [ progression free survival ( PFS ) ] .</brief_summary>
	<brief_title>Study Bortezomib Dexamethasone With Without Elotuzumab Treat Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . Documented progression recent line therapy Measurable disease 1 3 prior line therapy Subjects may proteasome inhibitor naive receive prior proteasome inhibitor therapy provide follow criterion meet : 1 . The subject discontinue proteasome inhibitor due intolerance grade â‰¥ 3 toxicity 2 . The subject refractory proteasome inhibitor , define progression treatment within 60 day last dose 3 . The subject previously achieve partial response ( PR ) well previous proteasome inhibitor ( PI ) Monoclonal gammopathy undetermined significance ( MGUS ) , smolder myeloma , Waldenstrom 's macroglobulinemia Active plasma cell leukemia Known Human immunodeficiency virus ( HIV ) infection active hepatitis A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Relapsed/Refractory Multiple Myeloma</keyword>
</DOC>